PUBLISHER: KBV Research | PRODUCT CODE: 1335786
PUBLISHER: KBV Research | PRODUCT CODE: 1335786
Asia Pacific Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The Asia Pacific Retinal Biologics Market would witness market growth of 6.3% CAGR during the forecast period (2023-2030).
Eye problems like retinal vein blockage also requires the use of retinal biologics. The National Library of Medicine reported in May 2023 that central retinal vein blockage is one of the leading causes of unexpected, painless vision loss in individuals. The prevalence of central retinal vein occlusion is 0.8 per 1000, and the prevalence of retinal vein occlusions is 5.20 per 1000 in the industrialized world. The prevalence and incidence of retinal fuels consumer desire for efficient treatment choices and boosts market expansion.
Due to increased healthcare infrastructure, an increase in unmet healthcare requirements, and a rise in the prevalence of noncommunicable or chronic diseases like diabetes, the retinal biologics demand is predicted to grow rapidly in unexplored, emerging regions. Aside from that, the demand for better healthcare services is growing, and the government is making considerable expenditures to upgrade the healthcare infrastructure. As a result, the healthcare sector in emerging economies is growing at a significant rate.
For many patients experiencing diabetic retinopathy, wet AMD, and macular edema from RVO or retina vein occlusion, anti-VEGF medication, the mainstay for many retinal illnesses frequently seen in a retina practice, can prevent further vision loss and restore visual function. Agents now on the market that have received approval include aflibercept (Eylea, Regeneron), ranibizumab (Lucentis, Genentech/Roche), and brolucizumab (Beovu, Novartis). Hence, the market will expand gradually throughout the forecast period, owing to the increasing prevalence of eye problems, their rising awareness, and the increasing R&D and approvals of retinal biologics.
According to the Organisation for Economic Co-operation and Development (OECD), about 227 million individuals in the Asia Pacific region have type 2 diabetes, and about half of them are untreated and uninformed that they will experience long-term consequences. The prevalence of diabetes among adults in the Asia Pacific nations ranged from 5.5% in Australia to 18.9% in Fiji for women and from 5.5% in Vietnam to 15.9% in Fiji for men. In this region, hyperglycemia, high pressure, dyslipidemia, and obesity were the most prevalent modifiable risk factors for DR. In the past few years, the implementation of systematic screening programs for DR and improvement in telemedicine screening methods have boosted patient coverage and cost-effectiveness. Thus, with the rise of awareness and prevalence of disease, the regional market will grow rapidly throughout the forecast period.
The China market dominated the Asia Pacific Retinal Biologics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,010.8 million by 2030. The Japan market is registering a CAGR of 5.5% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.7% during (2023 - 2030).
Based on Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Drug Class, the market is segmented into VEGF-A Antagonist and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.
Scope of the Study
Market Segments covered in the Report:
By Indication
- Macular Degeneration
- Diabetic Retinopathy
- Others
By Drug Class
- VEGF-A Antagonist
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- Novartis AG
- Amgen, Inc.
- AbbVie, Inc.
- Bayer AG
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- Bausch Health Companies, Inc.
- F. Hoffmann-La Roche Ltd.
- MeiraGTx Holdings plc
- Oxurion NV
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Asia Pacific Retinal Biologics Market, by Indication
- 1.4.2 Asia Pacific Retinal Biologics Market, by Drug Class
- 1.4.3 Asia Pacific Retinal Biologics Market, by Distribution Channel
- 1.4.4 Asia Pacific Retinal Biologics Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market at a Glance
- 2.1 Key Highlights
Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.1.1 Overview
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.3 Porter's Five Forces Analysis
Chapter 4. Strategies deployed in Retinal Biologics Market
Chapter 5. Asia Pacific Retinal Biologics Market by Indication
- 5.1 Asia Pacific Macular Degeneration Market by Country
- 5.2 Asia Pacific Diabetic Retinopathy Market by Country
- 5.3 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Retinal Biologics Market by Drug Class
- 6.1 Asia Pacific VEGF-A Antagonist Market by Country
- 6.2 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Retinal Biologics Market by Distribution Channel
- 7.1 Asia Pacific Hospital Pharmacy Market by Country
- 7.2 Asia Pacific Retail Pharmacy Market by Country
- 7.3 Asia Pacific Online Pharmacy Market by Country
Chapter 8. Asia Pacific Retinal Biologics Market by Country
- 8.1 China Retinal Biologics Market
- 8.1.1 China Retinal Biologics Market by Indication
- 8.1.2 China Retinal Biologics Market by Drug Class
- 8.1.3 China Retinal Biologics Market by Distribution Channel
- 8.2 Japan Retinal Biologics Market
- 8.2.1 Japan Retinal Biologics Market by Indication
- 8.2.2 Japan Retinal Biologics Market by Drug Class
- 8.2.3 Japan Retinal Biologics Market by Distribution Channel
- 8.3 India Retinal Biologics Market
- 8.3.1 India Retinal Biologics Market by Indication
- 8.3.2 India Retinal Biologics Market by Drug Class
- 8.3.3 India Retinal Biologics Market by Distribution Channel
- 8.4 South Korea Retinal Biologics Market
- 8.4.1 South Korea Retinal Biologics Market by Indication
- 8.4.2 South Korea Retinal Biologics Market by Drug Class
- 8.4.3 South Korea Retinal Biologics Market by Distribution Channel
- 8.5 Singapore Retinal Biologics Market
- 8.5.1 Singapore Retinal Biologics Market by Indication
- 8.5.2 Singapore Retinal Biologics Market by Drug Class
- 8.5.3 Singapore Retinal Biologics Market by Distribution Channel
- 8.6 Malaysia Retinal Biologics Market
- 8.6.1 Malaysia Retinal Biologics Market by Indication
- 8.6.2 Malaysia Retinal Biologics Market by Drug Class
- 8.6.3 Malaysia Retinal Biologics Market by Distribution Channel
- 8.7 Rest of Asia Pacific Retinal Biologics Market
- 8.7.1 Rest of Asia Pacific Retinal Biologics Market by Indication
- 8.7.2 Rest of Asia Pacific Retinal Biologics Market by Drug Class
- 8.7.3 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel
Chapter 9. Company Profiles
- 9.1 Novartis AG
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 Recent strategies and developments:
- 9.1.5.1 Acquisition and Mergers:
- 9.1.6 SWOT Analysis
- 9.2 Amgen, Inc.
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
- 9.3 AbbVie, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Regional Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 Recent strategies and developments:
- 9.3.5.1 Partnerships, Collaborations, and Agreements:
- 9.3.5.2 Approvals & Trials:
- 9.3.6 SWOT Analysis
- 9.4 Bayer AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 SWOT Analysis
- 9.5 Regeneron Pharmaceuticals, Inc.
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Research & Development Expense
- 9.5.4 SWOT Analysis
- 9.6 Santen Pharmaceutical Co., Ltd.
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Regional Analysis
- 9.6.4 Research & Development Expenses
- 9.6.5 SWOT Analysis
- 9.7 Bausch Health Companies, Inc.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Segmental and Regional Analysis
- 9.7.4 Research & Development Expense
- 9.7.5 Recent strategies and developments:
- 9.7.5.1 Partnerships, Collaborations, and Agreements:
- 9.7.5.2 Approvals & Trials:
- 9.7.5.3 Acquisition and Mergers:
- 9.7.6 SWOT Analysis
- 9.8 F. Hoffmann-La Roche Ltd.
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Segmental and Regional Analysis
- 9.8.4 Research & Development Expense
- 9.8.5 Recent strategies and developments:
- 9.8.5.1 Partnerships, Collaborations, and Agreements:
- 9.8.5.2 Approvals & Trials:
- 9.8.6 SWOT Analysis
- 9.9 MeiraGTx Holdings plc
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Research & Development Expenses
- 9.9.4 SWOT Analysis
- 9.10. Oxurion NV
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Research & Development Expenses
- 9.10.4 SWOT Analysis
LIST OF TABLES
- TABLE 1 Asia Pacific Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 2 Asia Pacific Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 3 Asia Pacific Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 4 Asia Pacific Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 5 Asia Pacific Macular Degeneration Market by Country, 2019 - 2022, USD Million
- TABLE 6 Asia Pacific Macular Degeneration Market by Country, 2023 - 2030, USD Million
- TABLE 7 Asia Pacific Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
- TABLE 8 Asia Pacific Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
- TABLE 9 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
- TABLE 10 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
- TABLE 11 Asia Pacific Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 12 Asia Pacific Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 13 Asia Pacific VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
- TABLE 14 Asia Pacific VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
- TABLE 15 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
- TABLE 16 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
- TABLE 17 Asia Pacific Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 18 Asia Pacific Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 19 Asia Pacific Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
- TABLE 20 Asia Pacific Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
- TABLE 21 Asia Pacific Retail Pharmacy Market by Country, 2019 - 2022, USD Million
- TABLE 22 Asia Pacific Retail Pharmacy Market by Country, 2023 - 2030, USD Million
- TABLE 23 Asia Pacific Online Pharmacy Market by Country, 2019 - 2022, USD Million
- TABLE 24 Asia Pacific Online Pharmacy Market by Country, 2023 - 2030, USD Million
- TABLE 25 Asia Pacific Retinal Biologics Market by Country, 2019 - 2022, USD Million
- TABLE 26 Asia Pacific Retinal Biologics Market by Country, 2023 - 2030, USD Million
- TABLE 27 China Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 28 China Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 29 China Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 30 China Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 31 China Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 32 China Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 33 China Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 34 China Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 35 Japan Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 36 Japan Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 37 Japan Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 38 Japan Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 39 Japan Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 40 Japan Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 41 Japan Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 42 Japan Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 43 India Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 44 India Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 45 India Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 46 India Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 47 India Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 48 India Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 49 India Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 50 India Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 51 South Korea Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 52 South Korea Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 53 South Korea Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 54 South Korea Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 55 South Korea Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 56 South Korea Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 57 South Korea Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 58 South Korea Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 59 Singapore Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 60 Singapore Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 61 Singapore Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 62 Singapore Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 63 Singapore Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 64 Singapore Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 65 Singapore Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 66 Singapore Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 67 Malaysia Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 68 Malaysia Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 69 Malaysia Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 70 Malaysia Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 71 Malaysia Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 72 Malaysia Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 73 Malaysia Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 74 Malaysia Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 75 Rest of Asia Pacific Retinal Biologics Market, 2019 - 2022, USD Million
- TABLE 76 Rest of Asia Pacific Retinal Biologics Market, 2023 - 2030, USD Million
- TABLE 77 Rest of Asia Pacific Retinal Biologics Market by Indication, 2019 - 2022, USD Million
- TABLE 78 Rest of Asia Pacific Retinal Biologics Market by Indication, 2023 - 2030, USD Million
- TABLE 79 Rest of Asia Pacific Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 80 Rest of Asia Pacific Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
- TABLE 81 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 82 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 83 Key Information - Novartis AG
- TABLE 84 Key Information - Amgen, Inc.
- TABLE 85 Key information - AbbVie, Inc.
- TABLE 86 Key Information - Bayer AG
- TABLE 87 Key Information - Regeneron Pharmaceuticals, Inc.
- TABLE 88 Key Information - Santen Pharmaceutical Co., Ltd.
- TABLE 89 key information - Bausch Health Companies, Inc.
- TABLE 90 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
- TABLE 91 Key Information - MeiraGTx Holdings plc
- TABLE 92 Key Information - Oxurion NV
List of Figures
- FIG 1 Methodology for the research
- FIG 2 Asia Pacific Retinal Biologics Market, 2019 - 2030, USD Million
- FIG 3 Key Factors Impacting Retinal Biologics Market
- FIG 4 Porter's Five Forces Analysis - Retinal Biologics Market
- FIG 5 Asia Pacific Retinal Biologics Market share by Indication, 2022
- FIG 6 Asia Pacific Retinal Biologics Market share by Indication, 2030
- FIG 7 Asia Pacific Retinal Biologics Market by Indication, 2019 - 2030, USD Million
- FIG 8 Asia Pacific Retinal Biologics Market share by Drug Class, 2022
- FIG 9 Asia Pacific Retinal Biologics Market share by Drug Class, 2030
- FIG 10 Asia Pacific Retinal Biologics Market by Drug Class, 2019 - 2030, USD Million
- FIG 11 Asia Pacific Retinal Biologics Market share by Distribution Channel, 2022
- FIG 12 Asia Pacific Retinal Biologics Market share by Distribution Channel, 2030
- FIG 13 Asia Pacific Retinal Biologics Market by Distribution Channel, 2019 - 2030, USD Million
- FIG 14 Asia Pacific Retinal Biologics Market share by Country, 2022
- FIG 15 Asia Pacific Retinal Biologics Market share by Country, 2030
- FIG 16 Asia Pacific Retinal Biologics Market by Country, 2019 - 2030, USD Million
- FIG 17 SWOT Analysis: Novartis AG
- FIG 18 Swot Analysis: Amgen, Inc.
- FIG 19 Swot Analysis: AbbVie, Inc.
- FIG 20 Swot Analysis: Bayer AG
- FIG 21 Swot Analysis: Regeneron Pharmaceuticals, Inc.
- FIG 22 Swot Analysis: Santen Pharmaceutical Co., Ltd.
- FIG 23 Recent strategies and developments: Bausch Health Companies, Inc.
- FIG 24 Swot Analysis: Bausch Health Companies, Inc.
- FIG 25 Swot Analysis: F. Hoffmann-La Roche Ltd.
- FIG 26 Swot Analysis: MeiraGTx Holdings plc
- FIG 27 Swot Analysis: Oxurion NV
